Literature DB >> 1662635

Gynaecological tissue levels of azithromycin.

K Krohn1.   

Abstract

In an open study the concentrations of azithromycin in plasma, urine, peritoneal fluid and gynaecological tissue in 20 patients undergoing elective gynaecological surgery were compared. Patients were allocated to one of four groups and all patients received a single 500 mg oral dose of azithromycin prior to surgery. In Group I, the dose was administered 24 h before surgery. In Groups II, III and IV it was administered 48, 72 and 96 h, respectively, prior to surgery. A total of 19 patients completed the study; one patient had peri-operative complications and did not proceed to surgery. High concentrations of azithromycin were found in gynaecological tissue up to 96 h after administration. The mean maximum observed concentration 24 h after administration was 1.44 +/- 0.22 micrograms/g. Using all data, the depletion rate constant was 0.0104 h-1, equivalent to a half-life of approximately 67 h. The mean concentration of drug in peritoneal fluid was approximately 9% of the mean concentration in gynaecological tissue. Tissue and peritoneal fluid azithromycin concentrations were much higher than plasma levels at the time of surgery. Detectable plasma levels were only found in four patients from Groups I and II. Six percent of the total dose was excreted in the urine during the seven-day period after drug administration. The single dose of azithromycin was well tolerated by all the patients in this study and no treatment-related side effects or laboratory test abnormalities were seen. It is concluded that a single 500 mg oral dose of azithromycin produces high and sustained levels in gynaecological tissue up to 96 h after administration.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1662635     DOI: 10.1007/bf01975844

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  7 in total

Review 1.  Pharmacokinetics of Erythromycin in man.

Authors:  J T Wilson; C J van Boxtel
Journal:  Antibiot Chemother (1971)       Date:  1978

2.  In-vitro activity of azithromycin, erythromycin, ciprofloxacin and norfloxacin against Neisseria gonorrhoeae, Haemophilus ducreyi, and Chlamydia trachomatis.

Authors:  L Slaney; H Chubb; A Ronald; R Brunham
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

3.  Comparison of the acid stability of azithromycin and erythromycin A.

Authors:  E F Fiese; S H Steffen
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

4.  Azithromycin in the treatment of sexually transmitted disease.

Authors:  O Steingrimsson; J H Olafsson; H Thorarinsson; R W Ryan; R B Johnson; R C Tilton
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

5.  The pharmacokinetics of azithromycin in human serum and tissues.

Authors:  G Foulds; R M Shepard; R B Johnson
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

6.  In vitro comparison of the activity of doxycycline, tetracycline, erythromycin and a new macrolide, CP 62993, against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.

Authors:  M Rylander; H O Hallander
Journal:  Scand J Infect Dis Suppl       Date:  1988

7.  Erythromycin: a microbial and clinical perspective after 30 years of clinical use (1).

Authors:  J A Washington; W R Wilson
Journal:  Mayo Clin Proc       Date:  1985-03       Impact factor: 7.616

  7 in total
  6 in total

Review 1.  Spectrum of activity of azithromycin.

Authors:  J D Williams
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

2.  Azithromycin versus Doxycycline for Urogenital Chlamydia trachomatis Infection.

Authors:  William M Geisler; Apurva Uniyal; Jeannette Y Lee; Shelly Y Lensing; Shacondra Johnson; Raymond C W Perry; Carmel M Kadrnka; Peter R Kerndt
Journal:  N Engl J Med       Date:  2015-12-24       Impact factor: 91.245

Review 3.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 4.  Azithromycin clinical pharmacokinetics.

Authors:  N J Lalak; D L Morris
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

5.  Pharmacokinetics of a single 1g dose of azithromycin in rectal tissue in men.

Authors:  Fabian Y S Kong; Thusitha W Rupasinghe; Julie A Simpson; Lenka A Vodstrcil; Christopher K Fairley; Malcolm J McConville; Jane S Hocking
Journal:  PLoS One       Date:  2017-03-28       Impact factor: 3.240

6.  Azithromycin (zithromax).

Authors:  J M McCarty
Journal:  Infect Dis Obstet Gynecol       Date:  1996
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.